P2RY13

Summary

P2RY13 (purinergic receptor P2Y13, HGNC:4537) is a protein-coding gene on chromosome 3q25.1, encoding P2Y purinoceptor 13 (Q9BPV8). Receptor for ADP.

The product of this gene belongs to the family of G-protein coupled receptors. This family has several receptor subtypes with different pharmacological selectivity, which overlaps in some cases, for various adenosine and uridine nucleotides. This receptor is activated by ADP.

Source: NCBI Gene 53829 — RefSeq curated summary.

At a glance

• Clinical variants (ClinVar): 1 total
• Druggable target: yes — 3 molecules with ChEMBL bioactivity
• MANE Select transcript: NM_176894

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:4537
Approved symbol	P2RY13
Name	purinergic receptor P2Y13
Location	3q25.1
Locus type	gene with protein product
Status	Approved
Aliases	FKSG77, P2Y13
Ensembl gene	ENSG00000181631
Ensembl biotype	protein_coding
OMIM	606380
Entrez	53829

Gene structure

Transcript identifiers

Ensembl transcripts: 1 — 1 protein_coding

ENST00000325602

RefSeq mRNA: 1 — MANE Select: NM_176894 NM_176894

CCDS: CCDS3158

Canonical transcript exons

ENST00000325602 — 2 exons

Exon	Start	End
ENSE00001619892	151326312	151329007
ENSE00001876920	151329481	151329549

Expression profiles

Bgee: expression breadth ubiquitous, 192 present calls, max score 96.63.

FANTOM5 (CAGE): breadth broad, TPM avg 8.9817 / max 1081.8020, expressed in 356 samples.

FANTOM5 promoters (1 alternative TSS)

Promoter ID	TPM avg	Samples expressed
45149	8.9817	356

Top tissues by expression

272 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
monocyte	CL:0000576	96.63	gold quality
mononuclear cell	CL:0000842	96.31	gold quality
leukocyte	CL:0000738	96.28	gold quality
blood	UBERON:0000178	94.59	gold quality
granulocyte	CL:0000094	92.52	gold quality
spleen	UBERON:0002106	90.03	gold quality
bone marrow	UBERON:0002371	88.92	gold quality
trabecular bone tissue	UBERON:0002483	87.64	gold quality
bone marrow cell	CL:0002092	86.33	gold quality
vermiform appendix	UBERON:0001154	84.83	gold quality
lymph node	UBERON:0000029	81.36	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	80.55	silver quality
inferior vagus X ganglion	UBERON:0005363	78.59	gold quality
palpebral conjunctiva	UBERON:0001812	77.53	gold quality
caecum	UBERON:0001153	77.12	gold quality
rectum	UBERON:0001052	76.61	gold quality
periodontal ligament	UBERON:0008266	74.37	gold quality
smooth muscle tissue	UBERON:0001135	73.24	gold quality
right lung	UBERON:0002167	72.68	gold quality
gall bladder	UBERON:0002110	72.28	gold quality
corpus callosum	UBERON:0002336	70.95	gold quality
spinal cord	UBERON:0002240	70.41	gold quality
C1 segment of cervical spinal cord	UBERON:0006469	70.28	gold quality
superior vestibular nucleus	UBERON:0007227	69.76	gold quality
prefrontal cortex	UBERON:0000451	69.12	gold quality
subthalamic nucleus	UBERON:0001906	67.66	silver quality
ventral tegmental area	UBERON:0002691	67.54	gold quality
midbrain	UBERON:0001891	67.53	gold quality
substantia nigra	UBERON:0002038	67.51	gold quality
upper lobe of left lung	UBERON:0008952	66.79	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	4.92

Regulation

Is transcription factor: no

Literature-anchored findings (GeneRIF, showing 11)

• (p2y13 purinoceptor) (PMID:11961076)
• results demonstrate a crosstalk between two metabotropic and one ionotropic purinergic receptor that regulates cAMP levels through adenylate cyclase 5 and modulates axonal elongation triggered by neurotropic factors and the PI3K-Akt-GSK3 pathway (PMID:22250198)
• The pattern of responsiveness to more selective P2-antagonists implies that both P2Y13 and P2X7 receptors are involved in Epsilon-toxin-of Clostridium perfringens induced hemolysis in human species. (PMID:30277122)
• Common p2y13 polymorphisms are associated with plasma inhibitory factor 1 and lipoprotein(a) concentrations, heart rate and body fat mass and may modulate cardiovascular risk. (PMID:30600215)
• P2Y13 and P2X7 receptors modulate mechanically induced adenosine triphosphate release from mast cells. (PMID:32155290)
• Nucleotides-Induced Changes in the Mechanical Properties of Living Endothelial Cells and Astrocytes, Analyzed by Atomic Force Microscopy. (PMID:33435130)
• Evaluation of tumor microenvironmental immune regulation and prognostic in lung adenocarcinoma from the perspective of purinergic receptor P2Y13. (PMID:34494914)
• Targeting the P2Y13 Receptor Suppresses IL-33 and HMGB1 Release and Ameliorates Experimental Asthma. (PMID:34860143)
• P2RY13 Exacerbates Intestinal Inflammation by Damaging the Intestinal Mucosal Barrier via Activating IL-6/STAT3 Pathway. (PMID:35982893)
• Erythrocytes from patients with ST-elevation myocardial infarction induce cardioprotection through the purinergic P2Y13 receptor and nitric oxide signaling. (PMID:36112326)
• P2Y13 receptor deficiency favors adipose tissue lipolysis and worsens insulin resistance and fatty liver disease. (PMID:38470490)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	p2ry13	ENSDARG00000069944
mus_musculus	P2ry13	ENSMUSG00000036362
rattus_norvegicus	P2ry13	ENSRNOG00000029756

Paralogs (6): GPR87 (ENSG00000138271), P2RY12 (ENSG00000169313), PTAFR (ENSG00000169403), GPR34 (ENSG00000171659), P2RY14 (ENSG00000174944), GPR171 (ENSG00000174946)

Protein

Protein identifiers

P2Y purinoceptor 13 — Q9BPV8 (reviewed: Q9BPV8)

Alternative names: G-protein coupled receptor 86, G-protein coupled receptor 94

All UniProt accessions (1): Q9BPV8

UniProt curated annotations — full annotation on UniProt →

Function. Receptor for ADP. Coupled to G(i)-proteins. May play a role in hematopoiesis and the immune system.

Subcellular location. Cell membrane.

Tissue specificity. Strong expression in spleen and adult brain. Lower expression in placenta, lung, liver, spinal cord, thymus, small intestine, uterus, stomach, testis, fetal brain, and adrenal gland. Not detected in pancreas, heart, kidney, skeletal muscle, ovary or fetal aorta. Clearly detected in lymph node and bone marrow, weakly detected in peripheral blood mononuclear cells (PBMC) and in peripheral blood leukocytes (PBL), but not detected in polymorphonuclear cells (PMN). In the brain, detected in all brain regions examined.

Miscellaneous. Stimulation by ADP in stably transfected CHO cells resulted in inhibition of adenylyl cyclase and the phosphorylation of the MAP kinases MAPK3 and MAPK1 in a pertussis toxin-sensitive way. Inhibition of adenylyl cyclase and phosphorylation of the MAP kinases are transduction mechanisms that involve G(i) proteins.

Similarity. Belongs to the G-protein coupled receptor 1 family.

Isoforms (2)

UniProt ID	Names	Canonical?
Q9BPV8-1	1	yes
Q9BPV8-2	2

RefSeq proteins (1): NP_795713* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR000276	GPCR_Rhodpsn	Family
IPR008109	P2Y13_rcpt	Family
IPR017452	GPCR_Rhodpsn_7TM	Domain

Pfam: PF00001

UniProt features (23 total): topological domain 8, transmembrane region 7, glycosylation site 3, chain 1, region of interest 1, disulfide bond 1, splice variant 1, sequence variant 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9BPV8-F1	83.33	0.56

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Disulfide bonds (1): 116–194

Glycosylation sites (3): 23, 31, 285

Function

Pathways and Gene Ontology

Reactome pathways

2 pathways

ID	Pathway
R-HSA-417957	P2Y receptors
R-HSA-418594	G alpha (i) signalling events

MSigDB gene sets: 171 (showing top): GOBP_G_PROTEIN_COUPLED_PURINERGIC_NUCLEOTIDE_RECEPTOR_SIGNALING_PATHWAY, REACTOME_P2Y_RECEPTORS, IVANOVA_HEMATOPOIESIS_MATURE_CELL, CEBPB_01, PICCALUGA_ANGIOIMMUNOBLASTIC_LYMPHOMA_UP, WTGAAAT_UNKNOWN, KEGG_NEUROACTIVE_LIGAND_RECEPTOR_INTERACTION, COATES_MACROPHAGE_M1_VS_M2_UP, AACTTT_UNKNOWN, GOBP_PURINERGIC_NUCLEOTIDE_RECEPTOR_SIGNALING_PATHWAY, REACTOME_CLASS_A_1_RHODOPSIN_LIKE_RECEPTORS, GOMF_TRANSMEMBRANE_SIGNALING_RECEPTOR_ACTIVITY, CHEN_METABOLIC_SYNDROM_NETWORK, GOMF_G_PROTEIN_COUPLED_RECEPTOR_ACTIVITY, chr3q25

GO Biological Process (4): G protein-coupled receptor signaling pathway (GO:0007186), signal transduction (GO:0007165), negative regulation of adenylate cyclase activity (GO:0007194), G protein-coupled purinergic nucleotide receptor signaling pathway (GO:0035589)

GO Molecular Function (3): G protein-coupled purinergic nucleotide receptor activity (GO:0045028), G protein-coupled receptor activity (GO:0004930), protein binding (GO:0005515)

GO Cellular Component (3): endoplasmic reticulum (GO:0005783), plasma membrane (GO:0005886), membrane (GO:0016020)

Reactome top-level categories

Rollup of top-2 pathways:

Category	Pathways
Nucleotide-like (purinergic) receptors	1
GPCR downstream signalling	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
G protein-coupled receptor activity	2
signal transduction	1
cell communication	1
cellular process	1
signaling	1
regulation of cellular process	1
cellular response to stimulus	1
adenylate cyclase activity	1
negative regulation of catalytic activity	1
regulation of adenylate cyclase activity	1
purinergic nucleotide receptor signaling pathway	1
purinergic nucleotide receptor activity	1
G protein-coupled purinergic nucleotide receptor signaling pathway	1
transmembrane signaling receptor activity	1
G protein-coupled receptor signaling pathway	1
binding	1
cytoplasm	1
endomembrane system	1
intracellular membrane-bounded organelle	1
membrane	1
cell periphery	1
cellular anatomical structure	1

Protein interactions and networks

STRING

1106 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
P2RY13	P2RY11	Q96G91	882
P2RY13	A0A0B4J1V8	A0A0B4J1V8	881
P2RY13	P2RX1	P51575	785
P2RY13	P2RX6	O15547	784
P2RY13	P2RX5	Q93086	708
P2RY13	P2RX2	Q9UBL9	701
P2RY13	P2RX3	P56373	696
P2RY13	ALDH18A1	P54886	638
P2RY13	TMEM119	Q4V9L6	627
P2RY13	P2RX4	Q99571	622
P2RY13	ADORA3	P0DMS8	602
P2RY13	TREM2	Q9NZC2	590
P2RY13	P2RX7	Q99572	559
P2RY13	P2RY4	P51582	545
P2RY13	ENTPD1	P49961	542

IntAct

4 interactions, top by confidence:

A	B	Type	Score
GJA8	P2RY13	psi-mi:“MI:0915”(physical association)	0.560
GJA8	P2RY13	psi-mi:“MI:0915”(physical association)	0.000
P2RY13	GJA8	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (2): P2RY13 (Two-hybrid), P2RY13 (Affinity Capture-MS)

ESM2 similar proteins: A5A4K9, B0F9W3, B2ZI34, F7EQ49, O08878, O35881, O54799, O93361, P21729, P24053, P28336, P30550, P32250, P33534, P34975, P35372, P41144, P41145, P42866, P43657, P46663, P52500, P55085, P55086, P79350, Q15391, Q2HJA4, Q2KIP6, Q3SX17, Q4G072, Q5IS39, Q63645, Q6GUG4, Q8BLG2, Q8BMC0, Q8BMP4, Q95254, Q95KC3, Q95M54, Q98907

Diamond homologs: D4A4Q2, O14626, O35881, P30992, P32250, Q15391, Q3SX17, Q3ZBK9, Q6GUG4, Q8BG55, Q95KC3, Q99MT7, Q9BE53, Q9BPV8, Q9BY21, Q9CPV9, Q9D8I2, Q9EPX4, Q9ESG6, Q9H244, O00254, P25105, Q28553, P60019, Q05394, Q3SAG9, Q6XCF2, Q9R1K6, Q9UPC5, B0UXR0, C8YUV0, E9QJ73, O02213, O08786, O09047, O16020, O42179, O55197, O57422, O70129

SIGNOR signaling

7 interactions.

A	Effect	B	Mechanism
P2RY13	“up-regulates activity”	GNAO1	binding
P2RY13	“up-regulates activity”	GNAQ	binding
P2RY13	“up-regulates activity”	GNA14	binding
P2RY13	“up-regulates activity”	GNA15	binding
P2RY13	“up-regulates activity”	GNA12	binding
P2RY13	“up-regulates activity”	GNA13	binding
ADP	“up-regulates activity”	P2RY13	“chemical activation”

Disease & clinical

Clinical variants and AI predictions

ClinVar

1 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	0
Likely benign	0
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

158 predictions. Top by Δscore:

Variant	Effect	Δscore
3:151329016:A:T	acceptor_gain	0.9900
3:151329023:A:C	acceptor_gain	0.9900
3:151329027:A:C	acceptor_gain	0.9900
3:151329476:TTCA:T	donor_loss	0.9900
3:151329008:C:CA	acceptor_loss	0.9800
3:151329009:T:A	acceptor_loss	0.9800
3:151329015:CAA:C	acceptor_gain	0.9800
3:151329497:A:AC	donor_gain	0.9800
3:151329498:G:C	donor_gain	0.9800
3:151329005:CAC:C	acceptor_gain	0.9700
3:151329209:TTTA:T	donor_gain	0.9700
3:151329008:C:CC	acceptor_gain	0.9600
3:151329025:A:C	acceptor_gain	0.9600
3:151329014:CCAA:C	acceptor_gain	0.9400
3:151329219:CCA:C	donor_gain	0.9400
3:151329497:AGTT:A	donor_gain	0.9400
3:151328535:A:C	acceptor_gain	0.9300
3:151329011:T:TC	acceptor_gain	0.9300
3:151329233:T:TA	donor_gain	0.9300
3:151329011:T:C	acceptor_gain	0.9200
3:151329015:C:T	acceptor_gain	0.9200
3:151329017:A:AC	acceptor_gain	0.9100
3:151329004:TCAC:T	acceptor_gain	0.9000
3:151329005:CACC:C	acceptor_gain	0.9000
3:151329022:CATA:C	acceptor_gain	0.8900
3:151329027:A:AC	acceptor_gain	0.8900
3:151328528:C:CT	acceptor_gain	0.8800
3:151329017:A:C	acceptor_gain	0.8800
3:151329221:A:AC	donor_gain	0.8700
3:151329025:A:AC	acceptor_gain	0.8600

AlphaMissense

2347 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
3:151328252:A:C	F268L	0.995
3:151328252:A:T	F268L	0.995
3:151328254:A:G	F268L	0.995
3:151328405:G:C	F217L	0.993
3:151328405:G:T	F217L	0.993
3:151328407:A:G	F217L	0.993
3:151328257:A:G	C267R	0.992
3:151328811:A:G	L82P	0.991
3:151328475:C:G	C194S	0.990
3:151328476:A:T	C194S	0.990
3:151328476:A:G	C194R	0.989
3:151328084:G:C	F324L	0.988
3:151328084:G:T	F324L	0.988
3:151328086:A:G	F324L	0.988
3:151328247:G:C	P270R	0.988
3:151328462:C:A	K198N	0.988
3:151328462:C:G	K198N	0.988
3:151328653:C:G	G135R	0.988
3:151328653:C:T	G135R	0.988
3:151328709:C:G	C116S	0.988
3:151328710:A:T	C116S	0.988
3:151328242:G:C	H272D	0.987
3:151328247:G:T	P270Q	0.987
3:151328443:A:G	W205R	0.987
3:151328443:A:T	W205R	0.987
3:151328554:A:G	W168R	0.987
3:151328554:A:T	W168R	0.987
3:151328710:A:G	C116R	0.987
3:151328884:C:G	G58R	0.986
3:151328160:T:A	K299I	0.985

dbSNP variants (sampled 300 via entrez): RS1000024182 (3:151329251 A>G), RS1000193151 (3:151329982 T>C,G), RS1000530433 (3:151328283 A>G), RS1001850633 (3:151327244 G>A), RS1002219977 (3:151326598 G>A), RS1002614891 (3:151326876 A>C,G), RS1003334575 (3:151330113 C>A), RS1005001415 (3:151328669 C>A,T), RS1005338738 (3:151327212 G>C,T), RS1005348804 (3:151326976 A>G), RS1006223421 (3:151326955 G>T), RS1006287847 (3:151327673 G>A), RS1006624364 (3:151326046 C>A), RS1006991854 (3:151326580 G>A), RS1007218444 (3:151330805 G>A)

Disease associations

OMIM: gene MIM:606380 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

0 associations (top):

Drugs & pharmacology

Drug and pharmacology data

Is drug target: yes

ChEMBL targets (2): CHEMBL3321651 (SINGLE PROTEIN), CHEMBL4524011 (PROTEIN FAMILY)

Molecules with ChEMBL bioactivity

3 molecules (phase ≥1), by development phase (incl. off-target/promiscuous compounds). Patent mentions across the top 20 by phase: 6,599 (via chembl_molecule»patent_compound — counts attach to the compound, not the gene–compound relationship, so off-target/promiscuous molecules can dominate).

Molecule	Name	Phase	Patents
CHEMBL334966	CANGRELOR	4	900
CHEMBL398435	TICAGRELOR	4	2,956
CHEMBL413376	SURAMIN HEXASODIUM	3	2,743

PharmGKB: 1 entry (VIP=true, CPIC=false)

GtoPdb / IUPHAR curated pharmacology

(IUPHAR/BPS Guide to Pharmacology — expert-curated)

Target class: gpcr — P2Y receptors

Most potent curated ligand interactions (15 total), top 15:

Ligand	Action	Affinity	Parameter
[33P]2MeSADP	Full agonist	9.6	pKd
2MeSADP	Full agonist	9.0	pIC50
cangrelor	Antagonist	8.3	pIC50
2MeSATP	Full agonist	7.7	pIC50
Ap4A	Antagonist	6.7	pIC50
ADP	Full agonist	6.5	pIC50
MRS2603	Antagonist	6.18	pIC50
MRS2211	Antagonist	5.97	pIC50
reactive blue-2	Antagonist	5.7	pIC50
ADPβS	Full agonist	5.7	pIC50
suramin	Antagonist	5.6	pIC50
2MeSAMP	Antagonist	5.6	pIC50
ATPγS	Full agonist	5.5	pIC50
ATP	Full agonist	5.4	pIC50
PPADS	Antagonist	4.9	pIC50

Binding affinities (BindingDB)

9 measured of 9 human assays (9 total across all organisms); most potent 9 below. Values come from heterogeneous assays and are not directly comparable.

Ligand	Measure	Value	Patent
ARL 69931MX	EC50	6320 nM	US-10220040: Compounds, compositions and methods useful for cholesterol mobilization
N-(2,3-dihydro-1,4-benzodioxin-6-yl)-2-(2-methoxyethylamino)acetamide	EC50	48900 nM	US-10220040: Compounds, compositions and methods useful for cholesterol mobilization
4-[1-[(3-hydroxy-4-methoxyphenyl)methyl]piperidin-4-yl]-2-piperidin-1-yl-1H-pyrimidin-6-one	EC50	299000 nM	US-10220040: Compounds, compositions and methods useful for cholesterol mobilization
4-[1-[[2-(methylamino)pyrimidin-5-yl]methyl]piperidin-4-yl]-2-piperidin-1-yl-1H-pyrimidin-6-one	EC50	6.63e+06 nM	US-10220040: Compounds, compositions and methods useful for cholesterol mobilization
ethyl (7S)-7-(2-chlorophenyl)-7-(6,7-dihydro-4H-thieno[3,2-c]pyridin-5-yl)-2,2-dimethylheptanoate	EC50	3.37e+07 nM	US-10220040: Compounds, compositions and methods useful for cholesterol mobilization
4-[1-[[2-(dimethylamino)pyrimidin-5-yl]methyl]piperidin-4-yl]-2-morpholin-4-yl-1H-pyrimidin-6-one	EC50	4.03e+07 nM	US-10220040: Compounds, compositions and methods useful for cholesterol mobilization
3,4-dihydro-1H-isochromen-1-yl(spiro[5H-pyrrolo[1,2-a]quinoxaline-4,4’-piperidine]-1’-yl)methanone	EC50	4.03e+07 nM	US-10220040: Compounds, compositions and methods useful for cholesterol mobilization
ethyl (7R)-7-(2-chlorophenyl)-7-(6,7-dihydro-4H-thieno[3,2-c]pyridin-5-yl)-2,2-dimethylheptanoate	EC50	4.24e+07 nM	US-10220040: Compounds, compositions and methods useful for cholesterol mobilization
8-[(3E)-3-(carboxymethylidene)-4-hydroxypiperidin-1-yl]-8-(2-chlorophenyl)-2,2-dimethyloctanoic acid	EC50	5.52e+07 nM	US-10220040: Compounds, compositions and methods useful for cholesterol mobilization

ChEMBL bioactivities

6 potent at pChembl≥5 of 8 total, top 6 by pChembl (potency: 10 = 0.1 nM, 6 = 1 µM).

pChembl	Type	Value	Unit	Molecule
6.18	IC50	660.7	nM	CHEMBL5281019
5.97	IC50	1072	nM	CHEMBL2219665
5.85	IC50	1398	nM	TICAGRELOR
5.72	IC50	1900	nM	RB 2
5.64	IC50	2300	nM	SURAMIN HEXASODIUM
5.20	EC50	6322	nM	CANGRELOR

PubChem BioAssay actives

5 with measured affinity, of 23 total; 5 most potent distinct compounds. Largely complementary to BindingDB; screening values are coarse (µM, 4 dp), so sub-nM hits tie at the floor.

Compound	Assay	Type	Value	Unit
[2-[(4-chloro-3-nitrophenyl)diazenyl]-4-formyl-5-hydroxy-6-methyl-3-pyridinyl]methyl dihydrogen phosphate	1953765: Antagonist activity at human P2Y13	ic50	0.6607	uM
[2-[(2-chloro-5-nitrophenyl)diazenyl]-4-formyl-5-hydroxy-6-methyl-3-pyridinyl]methyl dihydrogen phosphate	1953765: Antagonist activity at human P2Y13	ic50	1.0715	uM
Ticagrelor	1896871: Antagonist activity at human P2Y13R expressed in HEK293 cells assessed as inhibition of 2MeSADP-induced cAMP production preincubated for 0.5 hrs followed by 2MeSADP stimulation by cAMP-glo assay	ic50	1.3980	uM
trisodium;1-amino-4-[4-[[4-chloro-6-(3-sulfonatoanilino)-1,3,5-triazin-2-yl]amino]-3-sulfonatoanilino]-9,10-dioxoanthracene-2-sulfonate	1953764: Antagonist activity at P2Y13 (unknown origin)	ic50	1.9000	uM
hexasodium;8-[[4-methyl-3-[[3-[[3-[[2-methyl-5-[(4,6,8-trisulfonatonaphthalen-1-yl)carbamoyl]phenyl]carbamoyl]phenyl]carbamoylamino]benzoyl]amino]benzoyl]amino]naphthalene-1,3,5-trisulfonate	1953764: Antagonist activity at P2Y13 (unknown origin)	ic50	2.3000	uM

CTD chemical–gene interactions

16 total (human), top 16 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Nickel	decreases expression, increases expression	3
Air Pollutants	increases abundance, decreases expression, affects expression	2
triphenyl phosphate	affects expression	1
di-n-butylphosphoric acid	affects expression	1
MRS 2211	affects binding, decreases activity, decreases reaction, decreases response to substance, increases reaction	1
Arsenic Trioxide	increases expression	1
Adenosine Triphosphate	increases reaction, decreases reaction, decreases response to substance	1
Air Pollutants, Occupational	decreases expression	1
Cadmium	decreases expression, increases abundance	1
Hydrogen Peroxide	decreases reaction, decreases response to substance, increases reaction	1
Ozone	affects expression, increases abundance	1
Tetrachlorodibenzodioxin	decreases expression	1
Tretinoin	increases expression	1
Antirheumatic Agents	decreases expression	1
Cadmium Chloride	decreases expression, increases abundance	1
Particulate Matter	decreases expression, increases abundance	1

ChEMBL screening assays

12 unique, capped per target: 11 binding, 1 functional

Representative assays (with source publication via chembl_document):

Assay ID	Type	Description	Source paper
CHEMBL1070721	Binding	Inhibition of P2Y13 at 10 uM	Part II: piperazinyl-glutamate-pyridines as potent orally bioavailable P2Y12 antagonists for inhibition of platelet aggregation. — Bioorg Med Chem Lett
CHEMBL5153133	Functional	Antagonist activity at human P2Y13R expressed in HEK293 cells assessed as inhibition of 2MeSADP-induced cAMP production preincubated for 0.5 hrs followed by 2MeSADP stimulation by cAMP-glo assay	Discovery of a Series of 5-Amide-1H-pyrazole-3-carboxyl Derivatives as Potent P2Y14R Antagonists with Anti-Inflammatory Characters. — J Med Chem

Cellosaurus cell lines

1 cell lines: 1 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_ZD96	1321N1-HA-P2Y13	Cancer cell line	Male

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.